Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Cognitive tests and assessment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Of 234 patients, 143 (61.1%) were Aβ-positive. The area under the receiver operating characteristic curve for predicting MMSE score ≥ 20, ≥ 22 and ≥ 24 was 0.92, 0.90 and 0.91, respectively. High-sensitivity cutoffs, defined as scores that maximised specificity while maintaining sensitivity ≥ 80%, were HDS-R score ≥ 16, ≥ 17 and ≥ 18. Conversely, high-specificity cutoffs, defined as scores that maximised sensitivity while maintaining specificity ≥ 80%, were HDS-R score ≥ 19, ≥ 20 and ≥ 21, respectively. Subdomain analysis of MMSE and HDS-R showed Aβ-positive patients had lower scores in delayed recall and higher scores in calculation than Aβ-negative patients (all p < 0.01). In HDS-R subdomains, visual memory scores were also lower in Aβ-positive patients than in Aβ-negative patients (p < 0.01). The identified HDS-R cutoff scores were associated with MMSE-defined cognitive thresholds and may serve as a potential reference for identifying patients who could be eligible for anti-Aβ therapies. The cognitive profile observed in Aβ-positive patients was characterised by deficits in delayed recall and in visual memory and by relatively preserved calculation ability, suggesting a selective vulnerability pattern in early Alzheimer's disease.

What this study adds

Evidence grade: Low

This is a cross-sectional study of 234 participants. This study identified cutoff scores on one dementia scale that correspond to cognitive thresholds on another scale, which may help identify patients eligible for anti-amyloid therapies. Reported effect size: 61.1%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Yamakami, K., Matsubara, T., Fujita, K., Nakamura, K., Kihara, N., Sogawa, K., et al. (2025). Identification of Hasegawa Dementia Scale‐Revised Cutoff Scores Associated With Mini‐Mental State Examination Thresholds for Anti‐Amyloid β Therapies in Patients With Amnesia. Psychogeriatrics. https://doi.org/10.1111/psyg.70107

Vancouver

Yamakami K, Matsubara T, Fujita K, Nakamura K, Kihara N, Sogawa K, et al. Identification of Hasegawa Dementia Scale‐Revised Cutoff Scores Associated With Mini‐Mental State Examination Thresholds for Anti‐Amyloid β Therapies in Patients With Amnesia. Psychogeriatrics. 2025. doi:10.1111/psyg.70107. PMID: 41139981.

BibTeX

@article{yamakami2025-41139981,
  author  = {Yamakami, Kei and Matsubara, Tomoyasu and Fujita, Koji and Nakamura, Kazumi and Kihara, N. and Sogawa, Kazuki and Nakao, Ryota and Hanada, Kenta and others},
  title   = {{Identification of Hasegawa Dementia Scale‐Revised Cutoff Scores Associated With Mini‐Mental State Examination Thresholds for Anti‐Amyloid β Therapies in Patients With Amnesia}},
  journal = {Psychogeriatrics},
  year    = {2025},
  doi     = {10.1111/psyg.70107},
  pmid    = {41139981},
  url     = {https://doi.org/10.1111/psyg.70107}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study identified cutoff scores on one dementia scale that correspond to cognitive thresholds on another scale, which may help identify patients eligible for anti-amyloid therapies. It is a cross-sectional study about assessment and does not test whether the therapies work.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 4 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 42 of 100.42 of 100 points earned58 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Psychogeriatrics)
Journal's citation record 0 / 4 Psychogeriatrics: journal h-index 62 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 234 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Yuishin Izumi: h-index 44 (OpenAlex, whole career)
Institution's track record 0 / 3 Tokushima University: institution h-index 408 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41139981)
Free to read 2 / 2 Free to read
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Cognitive tests and assessment from nearby years

Also tagged “prevalence”

1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →